BAYER AG

DelveInsight's 'Hemophilia B Pipeline Insight, 2024' report details the global Hemophilia B treatment market, including clinical trials, therapies, and company developments. Key companies and therapies in various stages of development are highlighted, along with market drivers and barriers.

DelveInsight's 'Adrenoleukodystrophy Pipeline Insight, 2024' report details 11+ treatment therapies by 10+ companies, including Autobahn Therapeutics, Viking Therapeutics, and SwanBio Therapeutics. Emerging therapies like ABX-002, VK0214, and SBT101 are expected to impact the market. Minoryx Therapeutics plans to re-examine Nezglyal's approval after CHMP's refusal.

Pharmaceutical industry inefficiencies stem from high costs per drug approval, frequent C-level executive changes, and strategic R&D restructuring unrelated to science. AI-drug discovery companies should commit to programs until Phase I completion to avoid waste and maximize patient benefit.

Organon plans to acquire Dermavant for up to $1.2 billion, gaining its commercialized plaque psoriasis drug Vtama, which is under FDA review for atopic dermatitis. Vtama sales grew to $75.1 million in FY2023, but face competition in a crowded market. Organon aims to leverage its global scale to expand Vtama's reach.

Brands2Life appoints Isabelle Scali as head of pharma to lead new service aiding pharmaceutical companies in navigating health and technology, aiming for more agile and creative healthcare communications.

PD-1 inhibition with pembrolizumab before and after surgery significantly improves 5-year overall survival (86.6% vs 81.7%) in high-risk early triple-negative breast cancer, according to KEYNOTE-522 trial results.

Darolutamide plus ADT significantly reduced the risk of radiological progression or death by 46% in patients with metastatic hormone-sensitive prostate cancer (mHSPC), with consistent benefits across subgroups. Treatment emergent adverse events were low and similar between groups. The ARANOTE trial results were presented at the 2024 ESMO Congress and published in The Journal of Clinical Oncology, supporting the potential of darolutamide as a foundational therapy in prostate cancer.

The HIMALAYA study's 5-year survival analysis shows 19.6% survival with STRIDE (durvalumab plus tremelimumab) vs 9.4% with sorafenib in unresectable hepatocellular carcinoma, with no new safety concerns.

Bayer's darolutamide plus ADT reduced radiological progression or death risk by 46% in mHSPC patients, with positive data both with and without docetaxel. The results were presented at the 2024 ESMO Congress and published in The Journal of Clinical Oncology. Bayer plans to submit the ARANOTE trial data to health authorities for expanded darolutamide use in mHSPC.

The Renal Cell Carcinoma Clinical Trial Pipeline Market is projected to grow significantly from 2024 to 2031, driven by technological innovations, rising demand, and regulatory changes. The market is segmented by type and application, with key players including Amgen, AstraZeneca, and Pfizer. Clinical trials focus on novel therapies, drug combinations, and targeted treatments, aiming to improve outcomes for renal cell carcinoma patients.